Celyad Oncology Stock Quote CYAD - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.47

Bid

0.47

Ask

0.52

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

12.429M

Previous Close

0.47

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

41,429,000

Dividend Yield

PE Ratio

-1.47

Earnings Per Share (EPS)

-0.2

Revenue

102k

Net Profit

-8.45M

Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm h... Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.celyad.com

Headquarters

Wavre, Walloon Brabant, Bel

Founded

1970

Celyad Oncology SA is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CYAD. The last closing price for Celyad Oncology was $0.47. Over the last year, Celyad Oncology shares have traded in a share price range of $ 0.00 to $ 0.00.

Celyad Oncology currently has 41,429,000 shares outstanding. The market capitalization of Celyad Oncology is $12.43 million. Celyad Oncology has a price to earnings ratio (PE ratio) of -1.47.

Celyad Oncology publie ses résultats financiers pour l'année 2023 ainsi que les récents évènements marquants

Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (la “Société”), annonce aujourd'hui ses résultats financiers pour l'année 2023 au 31 décembre 2023 et présente une mise...

Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights

Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the “Company”), today announces its financial results for the fiscal year 2023 ended December 31, 2023, and provides a...

Celyad Oncology Announces Intention to Terminate SEC Reporting Obligations

Regulatory News: Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that it will voluntarily file a Form 15F with the United States Securities and Exchange...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Celyad Oncology fait le point sur les activités du quatrième trimestre 2023 et présente ses perspectives pour 2024

Trois piliers principaux pour libérer le potentiel des plateformes technologiques propriétaires et de la propriété intellectuelle : Une plateforme technologique exclusive sans édition de génome...

Celyad Oncology Provides Fourth Quarter 2023 Business Update and 2024 Outlook

Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC

(Article 14 §1 of the Law of 2 May 2007) Regulatory News: Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) today announces, in...

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Regulatory News: Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces that 6,500,000 shares of CFIP CLYD (UK) Limited benefit from a double voting right as of...

Celyad Oncology SA : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007)

Regulatory News: Celyad Oncology SA (Euronext : CYAD) (la « Société » ou « Celyad Oncology ») annonce en ce jour que 6.500.000 actions de CFIP CLYD (UK) Limited bénéficient d’un double droit de...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AKANAkanda Corporation	$ 6.29 (163.18%)	5.51M
NCPLNetcapital Inc	$ 0.2976 (70.25%)	38.77M
HLTHCue Health Inc	$ 0.1366 (44.86%)	52.62M
VSTMVerastem Inc	$ 16.30 (33.83%)	51.38k
CMBMCambium Networks Corporation	$ 4.00 (22.32%)	10
SLNHSoluna Holdings Inc	$ 1.40 (-43.78%)	1.19k
SNSESensei Biotherapeutics Inc	$ 0.83 (-42.76%)	102.32k
GNLXGenelux Corporation	$ 3.51 (-23.70%)	758
ASTIAscent Solar Technologies Inc	$ 0.175 (-18.49%)	6.58M
ZCARZoomcar Holdings Inc	$ 0.2126 (-17.28%)	537.82k
HLTHCue Health Inc	$ 0.1366 (44.86%)	52.62M
NCPLNetcapital Inc	$ 0.2976 (70.25%)	38.77M
GWAVGreenwave Technology Solutions Inc	$ 0.087 (-1.81%)	19.85M
LUCYInnovative Eyewear Inc	$ 0.2131 (14.57%)	11M
ASTIAscent Solar Technologies Inc	$ 0.175 (-18.49%)	6.58M